EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Artificial intelligence and circulating tumor DNA minimal residual disease in perioperative resectable non-small cell lung cancer

Yang Chen, Wenqi Li, Pengxuan Qiu, Ran Zhong, Boao Jiang, Miao He, Peiling Chen, Huiting Liu, Rui Gao, Xinting Li, Hongsheng Deng, Yu Jiang, Yuechun Lin, Wenhua Liang, Jianxing He, Hengrui Liang

Artificial Intelligence Surgery · 2026-07-15 · 6 (3) · 340-59

DOI: 10.20517/ais.2026.27 ↗
AbstractBibliografische Angaben

Abstract

Despite curative-intent treatment, recurrence risk in resectable non-small cell lung cancer (NSCLC) remains difficult to define, and postoperative management still depends on imperfect clinicopathologic assessment. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) has emerged as a promising adjunct for postoperative risk stratification, early relapse detection, and perioperative response assessment. Its clinical translation, however, is still limited by low sensitivity in low-shedding diseases, imperfect specificity from biological background signals, interpretive uncertainty, and a lack of assay standardization. In this context, artificial intelligence (AI) is relevant not as a generic add-on, but as a potential means to improve weak-signal detection, refine variant-origin assignment, and translate serial ctDNA measurements into clinically interpretable risk estimates. This review considers the current clinical role of ctDNA-MRD in perioperative NSCLC, the barriers to routine implementation, and the extent to which AI may help make molecular monitoring more reliable and clinically useful.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →